Skip to main content
Clinical Trials/NCT05228847
NCT05228847
Not yet recruiting
Not Applicable

Effect of Human Milk-derived Fortifiers on Weight Gain in Preterm Infants <1250 g: A Randomized Controlled Trial

University of Calgary1 site in 1 country42 target enrollmentJanuary 15, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postnatal Growth Restriction
Sponsor
University of Calgary
Enrollment
42
Locations
1
Primary Endpoint
Average weight gain
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Human Milk alone is unable to meet the high nutritional requirements of preterm infants. The American Academy of Pediatrics recommends fortification of human milk as a standard practice in all very low birth weight (VLBW) infants. Multi-nutrient human milk fortifiers (HMFs) are designed to meet the macro and micro-nutrient needs of VLBW infants. HMFs differ by the origin of milk and by nutrient composition. Traditionally, bovine milk has been the main source of multi-nutrient HMFs.

Detailed Description

Recent advances in lacto-engineering techniques allowed the manufacturing of multi-nutrient HMF from human milk as an alternative to bovine milk. Since exposure to infant bovine-based formula feeds is frequently shown to increase neonatal morbidities, human milk-derived HMFs (H-HMFs) have been frequently proposed to minimize exposure to bovine products prior to 34 weeks gestation with an intent to decrease the risks of necrotizing enterocolitis and feeding intolerance. The use of multi-nutrient H-HMFs is a promising intervention however currently available H-HMFs are expensive. The main objective of this randomized controlled trial is to compare the weight gain achieved by preterm infants born \<1250 g and fed human milk fortified with H-HMFs (made from mother's own milk (MOM) when MOM supply exceeds the daily need of her preterm infant or from donor human milk (DHM) compared with counterparts fed human milk fortified with the currently used bovine-derived fortifier (B-HMF).

Registry
clinicaltrials.gov
Start Date
January 15, 2023
End Date
May 30, 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Belal Alshaikh

Clinical Associate Professor, Department of Pediatrics

University of Calgary

Eligibility Criteria

Inclusion Criteria

  • Birthweight between 400 g-1250 g
  • Less than or 32 weeks gestational age at birth
  • Subject has been classified as appropriate for gestational age
  • Enteral feeding of human milk is initiated by 72 hours
  • Subject is expected to be on human milk for at least 3 weeks.

Exclusion Criteria

  • Congenital abnormalities or underlying disease that may affect growth
  • Maternal cocaine, alcohol, or opioid abuse during pregnancy
  • Mother or infant is currently receiving treatment for HIV infection
  • Infant with major surgery

Outcomes

Primary Outcomes

Average weight gain

Time Frame: up to 3 weeks

Average weight gain measured as g/kg per day

Secondary Outcomes

  • Head circumference(Weekly for 8 weeks)
  • Length(Weekly for 8 weeks)
  • Feed intolerance(3 weeks)
  • Electrolytes abnormalities(3 weeks)
  • Need for additional signal nutrient supplementation(3 weeks)

Study Sites (1)

Loading locations...

Similar Trials